MMRF, University of Michigan to Begin Personalized Multiple Myeloma Profiling Initiative
The Multiple Myeloma Research Foundation (MMRF) and the University of Michigan have partnered to provide multiple myeloma patients and their doctors access to…
News
Myeloma Therapies Advancing Rapidly, Says Expert at Sloan Kettering
In a video posted on Healio’s Hematology-Oncology page, Dr. Ola Landgren, chief of the myeloma service at Memorial Sloan Kettering Cancer Center…
Thalidomide Seen as Superior Pre-Stem Cell Transplant Therapy for Multiple Myeloma
A three-drug combination that includes thalidomide, in place of cyclophosphamide, prior to an autologous stem cell transplant was seen to improve response rates in multiple myeloma patients, according…
FDA Names Darzalex ‘Breakthrough Therapy’ for Previously Treated Multiple Myeloma Patients
The U.S. Food and Drug Administration has designated Darzalex (daratumumab), in combination with standard-of-care regimens, a breakthrough therapy for people with previously treated multiple myeloma (MM), speeding…
Drug Combo for Multiple Myeloma Fails in Overall Patient Survival
A randomized Phase 3 clincal trial has concluded that combining bortezomib (Velcade) with pegylated liposomal doxorubicin (PLD) does not show benefit in treating relapsed or refractory…
Immunotherapy Helps Myeloma Patients Who Relapse After Stem Cell Transplant, Study Shows
Many patients with blood cancers, such as myeloma, go into remission after receiving a stem-cell transplant. However, there are still many patients (about one-third) who relapse, a condition…
Elevated BMI Linked to Multiple Myeloma Development and Progression
A study has uncovered that elevated body mass index (BMI), a measurement of obesity, increases an individual’s risk of developing multiple myeloma and the disease’s…
Myeloma Development Might Be Stalled by Blocking Pathway from a Benign Condition, Study Says
Researchers at the University of Birmingham have found that blocking a specific mechanism in the benign condition monoclonal gammophaty of undetermined significance (MGUS) may prevent the development…
Risk of Myeloma Still Small Despite Newly Revealed Gene Mutations
In the largest study to date, researchers from The Institute of Cancer Research in London identified eight new gene mutations increasing the risk of developing…
EU OKs Extended Indication for Amgen’s Myeloma Drug Kyprolis
Global biotech firm Amgen has announced that the European Commission (EC) approved a variation to the marketing authorization for Kyprolis (carfilzomib) to be used in combination with…
